Semaglutide ( GLP1ra) is promoted as antidiabetic and anti obesity drug. There is increasing demand for this drug in America (USA) and many parts of the world. The trials found out the safety and efficacy of this drug. It resulted in shortage of the drug Semaglutide. So, alternates molecules are made available, but this brings us to a situation where we are concerned about the safety and efficacy of such alternate molecules which are not tested for their safety and effectiveness. So, FDA expressed its concern and given a warning and asked people to avoid using these molecules. It is more important to know for people buying the medications on-line to be cautious and aware of such directive from the FDA.
--------------------------------
https://www.medscape.com/viewarticle/992632?icd=login_success_email_match_norm
No comments:
Post a Comment